Palisade bio announces $2 million registered direct offering of common stock priced at market under nasdaq rules

Carlsbad, ca, sept. 07, 2023 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering.
PALI Ratings Summary
PALI Quant Ranking